# Efficacy and Safety of Lactoferrin in Heart Failure Patients

Study · id `cardio:ct-nct06427200` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06427200](<https://clinicaltrials.gov/study/NCT06427200>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06427200

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 114 participants.

## Technical summary

Registry record NCT06427200. Randomized; no masking; primary purpose treatment. Start 2024-07 (anticipated); primary completion 2027-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 114 participants (planned count; ClinicalTrials.gov record NCT06427200, source copy `cardio:ctgov-nct06427200-2024-05-24`, retrieved 2026-10-26)
- Planned start: 2024-07 (anticipated) (ClinicalTrials.gov record NCT06427200, source copy `cardio:ctgov-nct06427200-2024-05-24`, retrieved 2026-10-26)
- Primary completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT06427200, source copy `cardio:ctgov-nct06427200-2024-05-24`, retrieved 2026-10-26)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT06427200, source copy `cardio:ctgov-nct06427200-2024-05-24`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06427200-2024-05-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Lactoferrin in Heart Failure Patients
- Condition: Heart Failure With Reduced Ejection Fraction
- Intervention (Drug): oral Iron
- Intervention (Drug): Lactoferrin
- Intervention (Drug): lactoferrin and oral iron
- Lead sponsor: Cairo University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Cairo University (`cardio:org-cairo-university`)

## Provenance

Content hash: d38e07719e1a6c716b6dff5434b7f0acc91ead1f64ec74fe0d2ab2c7dd314fcb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
